Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
15 Diciembre 2022 - 6:00AM
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell
reprogramming company dedicated to developing curative cell
therapies for patients with solid tumors, announced that Lynn
Seely, MD, a member of the company’s board and former president and
chief executive officer (CEO) of Myovant Sciences, has been named
Lyell’s president & CEO effective today. Dr. Seely succeeds Ms.
Liz Homans following a four-year tenure as president and then CEO.
Ms. Homans will remain a consultant to the company through
June 2024.
Dr. Seely has extensive biopharmaceutical
leadership experience with a track record of success building
companies and developing new medicines in oncology and women’s
health. She was previously the president & CEO of Myovant
Sciences which gained marketing approval and launched ORGOVYX for
men with advanced prostate cancer and MYFEMBREE for women with
uterine fibroids and endometriosis. She was previously the chief
medical officer at Medivation for a decade where she oversaw the
development and marketing approval of XTANDI for men with
castration-resistant prostate cancer. She joined the Lyell Board in
May 2021 and serves as the lead independent director for Blueprint
Medicines. Dr. Seely trained in internal medicine at Yale-New
Haven Hospital, completed a basic science and clinical
fellowship in endocrinology and metabolism at the University of
California, San Diego where she was on faculty before joining
industry.
“My decision to transition from my role at Lyell
was a difficult one, but I am excited about the next chapter for
the company under Lynn’s leadership,” said Ms. Homans.
“Leading Lyell to become a fully integrated company with two
clinical stage programs has been a privilege. I am incredibly proud
of the team we have built and all that we have accomplished
together. Lynn’s expertise in leading teams to success on complex
rapidly moving programs is a perfect fit for this stage of Lyell’s
growth.”
“Liz has made tremendous contributions to Lyell,
building a strong foundation for the company and setting Lyell on a
trajectory for success. We support Liz in her decision and thank
her for her steadfast leadership,” said Rick Klausner, MD, chair of
Lyell Board of Directors. “Lynn is a proven leader with deep
industry expertise and a history of successfully leading oncology
clinical development programs. She has made significant
contributions as a board member, and we are delighted she has
enthusiastically agreed to step into this leadership position.”
“I am honored to be taking on this new role at
such an exciting time,” commented Lynn Seely, MD, Lyell’s president
and chief executive officer. “Since becoming a member of Lyell’s
board, I have been so impressed with Lyell’s groundbreaking
science, state-of-the-art manufacturing capabilities, and the
passion and commitment of the Lyell team to make a transformative
difference in the lives of patients with solid tumors. I look
forward to working even more closely with our exceptional team to
turn Lyell’s vision into reality.”
About Lyell Immunopharma,
Inc.
Lyell is a clinical-stage T-cell reprogramming
company dedicated to developing curative cell therapies for
patients with solid tumors. The company is advancing a pipeline of
therapies designed to address what it believes are the primary
barriers that limit consistent, reliable and curative responses to
adoptive T-cell therapy: T-cell exhaustion and lack of durable
stemness, which includes the ability to proliferate, persist and
self-renew, as well as generate differentiated effector cell
progenies to provide durable anti-tumor functionality. Lyell is
applying its proprietary ex vivo genetic and epigenetic
reprogramming technologies to address these barriers in order to
develop new medicines with improved, durable and potentially
curative clinical outcomes. Lyell is based in South San Francisco,
California with facilities in Seattle and Bothell, Washington. To
learn more, please visit www.lyell.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements expressed or implied
in this press release include, but are not limited to, statements
regarding: Lyell’s anticipated progress, business plans, business
strategy and clinical trials; Lyell advancing its pipeline or
growing its capabilities; the potential clinical benefits and
therapeutic potential of Lyell’s product candidates; the
anticipated benefits of the transition in management; the potential
of Lyell reprogramming technologies to help resist cell-exhaustion;
and other statements that are not historical fact. These statements
are based on Lyell’s current plans, objectives, estimates,
expectations and intentions, are not guarantees of future
performance and inherently involve significant risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, but are not limited to, risks and uncertainties related
to: the effects of the COVID-19 pandemic; geopolitical instability;
macroeconomic conditions; Lyell’s ability to submit planned INDs or
initiate or progress clinical trials on the anticipated timelines,
if at all; our lack of experience as a company in enrolling,
conducting or completing clinical trials; Lyell’s ability to
manufacture and supply its product candidates for its clinical
trials; the preclinical profiles of Lyell’s product candidates not
translating in clinical trials; the potential for results from
clinical trials to differ from preclinical, early clinical,
preliminary or expected results; significant adverse events,
toxicities or other undesirable side effects associated with
Lyell’s product candidates; the significant uncertainty associated
with Lyell’s product candidates ever receiving any regulatory
approvals; Lyell’s ability to obtain, maintain or protect
intellectual property rights related to its product candidates;
implementation of Lyell’s strategic plans for its business and
product candidates; the sufficiency of Lyell’s capital resources
and need for additional capital to achieve its goals; and other
risks, including those described under the heading “Risk Factors”
in Lyell’s most recently filed quarterly report on Form 10-Q and
subsequent filings with the SEC. Forward-looking statements
contained in this press release are made as of this date, and Lyell
undertakes no duty to update such information except as required
under applicable law.
Contact:Ellen RoseSenior Vice
President, Communications and Investor Relationserose@lyell.com
Lyell Immunopharma (NASDAQ:LYEL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Lyell Immunopharma (NASDAQ:LYEL)
Gráfica de Acción Histórica
De May 2023 a May 2024